AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03331289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Dapagliflozin will be administered to 20 subjects after a 3 hour tracer equilibration period
Study NCT03331289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide and Dapagliflozin
Description: Exenatide and Dapagliflozin will be administered to 20 subjects after a 3 hour tracer equilibration period
Study NCT04741620 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin 10microM (TRPV1 natural agonist)
Description: 10 mL Capsaicin 10microM solution 3 times per day (before each meal) during 14 consecutive days.
Study NCT04741620 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Capsaicin 10microM (TRPV1 natural agonist)
Description: 10 mL Capsaicin 10microM solution 3 times per day (before each meal) during 14 consecutive days.
Study NCT04741620 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Piperine 150microM (TRPV1 & TRPA1 natural agonist)
Description: 10 mL Piperine 150microM solution 3 times per day (before each meal) during 14 consecutive days.
Study NCT04741620 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Piperine 150microM (TRPV1 & TRPA1 natural agonist)
Description: 10 mL Piperine 150microM solution 3 times per day (before each meal) during 14 consecutive days.
Study NCT04741620 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cinnamaldehyde 756,6microM + zinc 70microM (TRPA1 natural agonist)
Description: 10 mL Cinnamaldehyde 756,6microM + zinc 70microM solution 3 times per day (before each meal) during 14 consecutive days.
Study NCT03458169 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapist LEAP session feedback
Description: A standard therapy session is being performed with a participant with the LEAP body-weight support robot. Subsequently, the therapist is answering a questionnaire to assess the clinical applicability of the robot. An observer will assess with a questionnaire whether use errors occurred during the session.
Study NCT03458169 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Participant LEAP session feedback
Description: A standard therapy session is being performed with a participant inside the LEAP body-weight support robot. Subsequently, the participant is answering a questionnaire to assess the comfort of the robot.
Study NCT03458169 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LEAP risk control validation
Description: The therapist rates the risk control measurements of the LEAP robot with a questionnaire, during a session with a member of the investigational team.
Study NCT04724889 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood test
Description: Blood test to check high sensitivity troponin. Additional blood biomarkers maybe added in light of new research
Study NCT02406157 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 577-MPL
Description: Device for 577nm micropulse treatment of the diabetic macular edema with the following parameters:100 microns spot size,5% duty cycle of 0.2 seconds,power is tested on micropulse mode and then reduce power to 50% of visible
Study NCT02406157 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 532-SLP
Description: Device for 532nm subthreshold treatment of the diabetic macular edema, by decomposing a subthreshold short pulse, with 10 milliseconds, 100 microns, and power(100-1000mW) adjusted according to patient's diopter transparency and pigmentation
Study NCT04130815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled furosemide
Description: 4ml of 10mg/ml solution of furosemide nebulized with small and large droplet sizes and inhaled with different breathing patterns
Study NCT01311778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Subjects in Arm CBD 400 mg will receive 400 mg of Cannabidiol in two test sessions along with 0.5 mcg/kg and 1mcg/kg of fentanyl.~Subjects in Arm CBD 800 mg will receive 800 mg of Cannabidiol in two test sessions along with 0.5 mcg/kg and 1mcg/kg of fentanyl.
Study NCT01311778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: All subjects will receive 0.5 mcg/kg and 1mcg/kg of Fentanyl (test session 1 and test session 2)
Study NCT01311778 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl
Description: All subjects will receive 0.5 mcg/kg and 1mcg/kg of Fentanyl (test session 1 and test session 2)
Study NCT02013219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Participants will receive 600 mg PO alectinib BID for 28 consecutive days during Cycle 1 and on Days 1-21 of each cycle thereafter (21-day cycles from Cycle 2 onwards) in Stage 1 and RP2D PO BID in Stage 2.
Study NCT02996786 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Danggui Buxue Tang
Description: Danggui Buxue Tang purchased from Kaiser Pharmaceutical
Study NCT02013219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will receive 1200 mg atezolizumab IV infusion q3w on Day 8 of Cycle 1 and on Day 1 of each cycle thereafter in Stage 1 and in Stage 2.
Study NCT02996786 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Consisting of corn starch and carboxymethyl cellulose
Study NCT04741620 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cinnamaldehyde 756,6microM + zinc 70microM (TRPA1 natural agonist)
Description: 10 mL Cinnamaldehyde 756,6microM + zinc 70microM solution 3 times per day (before each meal) during 14 consecutive days.
Study NCT01922297 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Day Treatment MDFT-HIV
Description: MDFT-HIV is a specialized intervention aimed at reducing risk factors for HIV-associated sexual behaviors. It builds protective behaviors in the adolescent's intrapersonal and interpersonal functioning, as well as those aspects of family functioning to reduce youths' high-risk sexual behavior. For instance, interventions target inadequate monitoring, parent-adolescent conflict, and parental disengagement - behaviors consistently associated with elevated HIV/STD risk. It facilitates positive and supportive family relationships, processes that can significantly reduce HIV/STD risk. Additionally, it aims to promote effective family communication about sexuality and safer sexual behaviors, among the most important protective factors against sexual risk taking behavior.
Study NCT01922297 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Day Treatment SAU
Description: Substance abuse treatment and HIV prevention services are routinely provided to youth in the day treatment programs. The day treatment programs contract to local substance abuse and mental health providers for these services that are provided both within and outside of the day treatment setting. The intervention's specific features are similar to those found in the literature on outpatient peer-based group treatment for adolescent alcohol abusers (CSAT 1998). Specifically, it is based on a cognitive-behavioral group treatment model (Kaminer et al 1998; Marshall \& Marshall 1993), with a comprehensive treatment package including individual counseling and treatment planning.
Study NCT04741620 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Citric acid 457,5microM (pH=3,5) (ASIC3 natural agonist)
Description: 10 mL Citric acid 457,5microM (pH=3,5) solution 3 times per day (before each meal) during 14 consecutive days.
Study NCT04741620 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Citric acid 457,5microM (pH=3,5) (ASIC3 natural agonist)
Description: 10 mL Citric acid 457,5microM (pH=3,5) solution 3 times per day (before each meal) during 14 consecutive days.
Study NCT04741620 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin 10microM + Citric acid 457,5microM (pH=3,5) (TRPV1 & ASIC3 natural agonists)
Description: 10 mL Capsaicin 10microM + Citric acid 457,5microM (pH=3,5) solution 3 times per day (before each meal) during 14 consecutive days.
Study NCT02115698 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Heavy Resistance Training
Description: Supervised Heavy Resistance Training three times weekly for 52 weeks.
Study NCT02115698 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Light Intensity Training
Description: Home-based Light Intensity Training three-five times weekly for 52 weeks.
Study NCT02115698 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein Whey
Description: Two daily 20 g whey protein and 10 g carbohydrate supplementations for 52 weeks.
Study NCT02115698 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein Whey
Description: Two daily 20 g whey protein and 10 g carbohydrate supplementations for 52 weeks.
Study NCT02115698 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein Collagen
Description: Two daily 20 g collagen protein and 10 g carbohydrate supplementations for 52 weeks.
Study NCT02115698 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Carbohydrate
Description: Two daily 30 g carbohydrate supplementations for 52 weeks.
Study NCT01334515 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hu14.18-IL2 fusion protein
Description: Given IV
Study NCT01334515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isotretinoin
Description: Given PO
Study NCT01334515 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given SC
Study NCT01334515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01311661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo twice daily
Description: Inhaled Placebo of Olodaterol twice daily
Study NCT01311661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol low daily dose twice daily
Description: Inhaled Olodaterol medium daily dose administered as low dose twice daily
Study NCT01311661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol medium daily dose twice daily
Description: Inhaled Olodaterol high daily dose administered as medium dose twice daily
Study NCT01311661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol high daily dose once daily and placebo
Description: Inhaled Olodaterol high daily dose administered as one full dose once daily and placebo once daily
Study NCT01311661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol medium daily dose once daily and placebo
Description: Inhaled Olodaterol medium daily dose administered as one full dose once daily and placebo once daily
Study NCT03670628 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shockwave therapy
Description: Each therapy session, lasting about 20 minutes, will deliver 720 shockwave therapy applied to the penis and to the left and right crus (shaft near the base)
Study NCT03670628 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham shockwave therapy
Description: Each therapy session, lasting about 20 minutes, will deliver sham shockwave therapy applied to the penis and to the left and right crus (shaft near the base)
Study NCT00832806 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Extended IVR (integrated voice response technology)
Description: See detailed description
Study NCT00832806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline (Champix)
Description: See detailed description
Study NCT00832806 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IVR treatment
Description: See detailed description
Study NCT01248975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP/SAL 250/50mcg BID
Description: FP/SAL 250/50mcg BID
Study NCT01248975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FP/SAL 250/50mcg BID
Description: FP/SAL 250/50mcg BID
Study NCT01248975 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FP/SAL 250/50mcg BID
Description: FP/SAL 250/50mcg BID
Study NCT01248975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915 200mg QD (AM)
Description: GSK2190915 200mg QD (AM)
Study NCT01248975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915 100mg QD (AM)
Description: GSK2190915 100mg QD (AM)
Study NCT01248975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast 10mg QD (PM)
Description: Montelukast 10mg QD (PM)
Study NCT01248975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo tablets (2) (AM)
Description: Placebo tablets (2) (AM)
Study NCT02013219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Participants will receive 150 mg erlotinib PO QD for 28 consecutive days during Cycle 1 and on Days 1-21 of each cycle thereafter in Stage 1 (21-day cycles from Cycle 2 onwards) and RP2D PO QD in Stage 2.
Study NCT01248975 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets (2) (AM)
Description: Placebo tablets (2) (AM)
Study NCT01248975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule (PM)
Description: Placebo capsule (PM)
Study NCT01248975 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule (PM)
Description: Placebo capsule (PM)
Study NCT01365611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine
Description: A single intranasal dose of 30 mg ketorolac tromethamine was administered to all subjects on Days 1 and 6.
Study NCT01365611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate
Description: Daily intranasal dose of 200 ug fluticasone propionate on Days 2-6
Study NCT03469804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Route: intravenous infusion Dose regimen: 200 mg per infusion every 3 weeks Duration of treatment: 6 months (8 cycles)
Study NCT04185727 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised strength training
Description: 12 weeks supervised strength training exposure. The study will allocate patients to groups consisting of 4 members who receive strength training for 12 weeks. The strength training program will consist of three weekly supervised strength exercise sessions, each 40-60 min of duration, which starts with a 10 min warm-up and are completed with a meditation/relax session.
Study NCT04632719 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The use of the MentalPlus® digital game for assessment and rehabilitation of cognitive function after remission of the symptoms of COVID-19
Description: Cognitive assessment and rehabilitation will be carried out on volunteers who have healed from COVID-19.
Study NCT04632719 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The use of the MentalPlus® digital game for assessment and rehabilitation of cognitive function after remission of the symptoms of COVID-19
Description: Cognitive assessment and rehabilitation will be carried out on volunteers who have healed from COVID-19.
Study NCT02222324 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 8 placebo tablets matching E2609
Study NCT02222324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2609
Description: E2609 will be administered as 8 tablets
Study NCT02222324 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Administered as 1 tablet with 7 tablets of placebo matching E2609
Study NCT02151201 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccination video education
Description: Influenza vaccination video education
Study NCT02151201 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Hand washing video education
Description: Hand washing video education
Study NCT01223677 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rumination Focused CBT
Description: see arms
Study NCT01674855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-G-CSF
Description: Prefilled syringe, 6mg/day, single dosing per cycle, for 6 cycle
Study NCT01674855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: Vial, 100ug/m2/day, multiple dosing per cycle(daily administration, up to 10 days), for 6 cycle
Study NCT01699828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Description: The buspirone will be given once as a tablet and encapsulated for blinding.
Study NCT01699828 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be lactose and encapsulated for blinding. A single capsule will be given.
Study NCT04391907 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IPL
Description: Intense pulse light (IPL) laser is used for the treatment of dry eye originated from meibomian gland dysfunction. IPL laser will be performed to patients who are planned to cataract surgery to improve dry eye.
Study NCT02566512 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Tracheostomy cuff inflation.
Description: With the tracheostomy cuff inflated, the peak expiratory flow meter will be attached directly to the tracheostomy tube. The patient will be instructed to take as big a breath as they can and then forcefully cough. This will be repeated four times.
Study NCT02566512 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Tracheostomy cuff deflation
Description: With the tracheostomy cuff deflated, a one-way valve will be attached to the tracheostomy tube. The patient will use a mouthpiece to connect to the peak expiratory flow meter. The patient will be instructed to take as big a breath as they can and then forcefully cough. This will be repeated four times
Study NCT00702676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine Fumarate
Description: Tablet, Oral, once daily
Study NCT04741620 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Capsaicin 10microM + Citric acid 457,5microM (pH=3,5) (TRPV1 & ASIC3 natural agonists)
Description: 10 mL Capsaicin 10microM + Citric acid 457,5microM (pH=3,5) solution 3 times per day (before each meal) during 14 consecutive days.
Study NCT04741620 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (Methyl benzoate, Propyl benzoate, Propylenglycol)
Description: 10 mL placebo solution 3 times per day (before each meal) during 14 consecutive days.
Study NCT02959762 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Control
Description: two placebo softgel capsules per day (for 8 weeks) containing no vitamin K2 (menaquinone-7)
Study NCT01835860 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Prostate artery embolization
Study NCT03067103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Patients will receive injections in peritonsillar fossa of tramadol (2 mg/kg-2 ml)
Study NCT02959762 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low-Dose Vitamin K2 (menaquinone-7; 45-mcg/d)
Description: one 45-mcg vitamin K2 (menaquinone-7) softgel capsule per day and one placebo softgel per day (containing no menaquinone-7) for 8 weeks
Study NCT02959762 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d)
Description: two 45-mcg vitamin K2 (menaquinone-7) softgel capsules per day for 8 weeks
Study NCT03106805 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: early insertion
Description: insertion at 4th postpartum week
Study NCT03106805 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: late insertion
Description: insertion at 6th postpartum week
Study NCT03292328 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Participants in the Yoga group will meet twice weekly for 8 weeks of classes taught by MSK yoga instructors. Each class will last for sixty minutes. In addition to these group classes, participants will utilize a home-based program on the days group classes are not held. The daily home practice will continue for four weeks after the group classes are finished.
Study NCT03292328 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wait List Control
Description: Participants in the WLC group will continue usual care for twelve weeks before participating in Yoga classes for eight weeks. At the end of the twelve week follow-up, these subjects will receive eight weeks of group Yoga classes and the home Yoga practice recording. At week 20, they will complete a final follow-up visit.
Study NCT01887691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eszopiclone
Description: Eszopiclone at a dose of 1-3 mg (lowest tolerated dose, as determined using a dose escalation schedule and side effect profile)will be taken 30 minutes before bedtime for one week.
Study NCT01143311 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Arm A
Description: 4 distinct biopsies will be taken~1. in a non UV-exposed area (inner arm)~2. in a UV-exposed area (external surface of the forearm)~3. in a pretumoral region (actinic keratosis)~4. inside the tumor
Study NCT02411903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin and clopidogrel
Description: Dose: atorvastatin 40mg/d plus clopidogrel 75mg/d for 9 months.
Study NCT03067103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Patients will receive injections in peritonsillar fossa of ketamine prior to surgery